Industry News
Pharmaceutical Industry News
The FDA has extended its target…
The FDA has extended its target action dates for two applications to expand the use of Eylea’s high-dose formulation. The U.S. regulator was originally scheduled to make its Eylea HD decisions by Aug. 19, but
Unregulated Sexual Stimulants Flood West Africa
Unregulated sexual stimulants claiming to be herbal remedies or pharmaceuticals are flooding the region. Officials are scrambling to address the issue.
A year after earning FDA approval…
A year after earning FDA approval for Kisunla, Eli Lilly is shining a light on the anti-amyloid Alzheimer’s disease therapy in its first branded campaign.
Swoop and iSpot have joined forces…
Swoop and iSpot have joined forces to deliver insights into cross-platform ad exposures against specific audience segments.
Catalent is laying off 350…
Catalent is laying off 350 employees at its gene therapy manufacturing division in Baltimore “due to an unexpected shift in demand from a large customer, which made it necessary to reduce our workforce,” a spokesperson
On a recent earnings call, the…
On a recent earnings call, the Danish drugmaker's newly appointed CEO signaled that he will look over the company's cost base.
A trio of Indian…
A trio of Indian drugmakers—Alembic, Sun and Glenmark—each issued separate voluntary drug recalls due to either the presence of carcinogens or foreign matter in the products.
With three new antibiotics set to…
With three new antibiotics set to shake up the stagnant treatment landscape for uncomplicated urinary tract infections in the U.S., Dublin-based Iterum Therapeutics has made it to market first, edging out generics juggernaut Alembic Pharmaceuticals
Several U.S. pharma companies that…
Several U.S. pharma companies that had posted revenue declines in the first quarter bounced back in the second quarter, including Pfizer, Regeneron and Bristol Myers Squibb. Additionally, Eli Lilly has finally surpassed Novo Nordisk in
The nation’s largest pediatrician…
The nation's largest pediatrician professional organization urged providers and insurers to consider its evidence-backed vaccine recommendations, as opposed to those coming out of a federal advisory panel the health secretary remade to reflect his skepticism
As its lead candidate advances…
As its lead candidate advances into a late-stage trial for pulmonary arterial hypertension, Inhibikase Therapeutics has picked up a commercial leader with plenty of experience in the PAH space.
With sales of atopic dermatitis…
With sales of atopic dermatitis treatment Adbry scaling up in the U.S., Leo Pharma is accomplishing one of the goals established by CEO Christophe Bourdon when he took over at the Danish dermatology specialist in
As it brings a brand beloved in…
As it brings a brand beloved in Mexico stateside, Bayer is stoking nostalgia and a sense of family and tradition to improve its reach among the Hispanic population in the U.S.
Dogged for several years by an…
Dogged for several years by an investor lawsuit accusing the company of misleading investors about the safety and efficacy of its now-approved drug Tavneos, ChemoCentryx has emerged victorious in a securities fraud complaint.
Un fármaco común para perder peso puede tratar una enfermedad hepática grave, según la FDA
Se ha aprobado el uso de Wegovy entre el creciente número de estadounidenses que padecen una enfermedad hepática asociada a una disfunción metabólica.
Wegovy Gets F.D.A. Approval for MASH
Wegovy has been approved for use among the growing number of Americans who have MASH.
Roche has found redemption in a…
Roche has found redemption in a precision medicine approach following an earlier Tecentriq trial flop in a broader bladder cancer population.
An appeals court overturned a…
An appeals court overturned a prior FDA action in a years-long face-off between Vanda and the agency over a delayed hearing for Vanda's jet lag disorder hopeful Hetlioz.
Several months after unveiling its…
Several months after unveiling its direct-to-consumer NovoCare Pharmacy service with the launch of a $499 cash-pay option for a monthly supply of Wegovy, Novo Nordisk is expanding the discount to its other GLP-1 heavyweight.
Sarepta Therapeutics has provided…
Sarepta Therapeutics has provided additional safety data on its gene therapy Elevidys as a Duchenne muscular dystrophy patient group petitions the FDA to update the medicine’s label.